Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Aeglea Biothera (AGLE)

Aeglea Biothera (AGLE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Aeglea: Q3 Earnings Snapshot

Aeglea: Q3 Earnings Snapshot

AGLE : 12.01 (+8.79%)
Aeglea BioTherapeutics Announces Grants of Inducement Awards

/PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the...

AGLE : 12.01 (+8.79%)
Aeglea BioTherapeutics to Participate in Upcoming September Conference

/PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the...

AGLE : 12.01 (+8.79%)
Aeglea BioTherapeutics Announces Reverse Stock Split

/PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the...

AGLE : 12.01 (+8.79%)
Aeglea BioTherapeutics Expands Executive Leadership Team with Appointment of Industry Veterans Scott Burrows and Heidy Abreu King-Jones

/PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the...

AGLE : 12.01 (+8.79%)
ARQT : 9.60 (+3.23%)
Aeglea: Q2 Earnings Snapshot

Aeglea: Q2 Earnings Snapshot

AGLE : 12.01 (+8.79%)
Aeglea BioTherapeutics Reports Second Quarter 2023 Financial Results

/PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea" or the "Company") (NASDAQ:AGLE), a biotechnology company advancing a pipeline of antibody therapeutics...

AGLE : 12.01 (+8.79%)
Aeglea BioTherapeutics Announces Sale of Pegzilarginase to Immedica Pharma

/PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ:AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with best-in-class...

AGLE : 12.01 (+8.79%)
Aeglea BioTherapeutics Announces Grant of Inducement Awards

/PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ: AGLE) today announced that, in connection with the acquisition of Spyre Therapeutics, Inc....

AGLE : 12.01 (+8.79%)
Increased Funding for Pancreatic Cancer Trials & Treatments Rising along with Demand for New Drugs

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:POAI),(NASDAQ:AGLE),(NASDAQ:TALS),(NASDAQ:MRTX) EQNX::TICKER_END

ONCY : 1.0100 (+2.02%)
ONC.TO : 1.41 (+2.92%)
AGLE : 12.01 (+8.79%)
TALS : 27.20 (-0.73%)
POAI : 1.0100 (-0.98%)
MRTX : 58.70 (-0.17%)

Barchart Exclusives

3 Mid-Cap Energy Dividend Stocks to Scoop Up Now
Amid predictions of higher oil prices, here are three dividend-paying energy stocks that are worth adding to your portfolio. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar